Clinical Trial Update: Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 rollover study of weekly paclitaxel (BMS-181339) in patients with advanced or recurrent esophageal cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Paclitaxel (BMS-181339) (paclitaxel)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-19